Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms.

St-Pierre D, Cabana J, Holleran BJ, Besserer-Offroy É, Escher E, Guillemette G, Lavigne P, Leduc R.

Biochem Pharmacol. 2018 Aug;154:104-117. doi: 10.1016/j.bcp.2018.04.021. Epub 2018 Apr 20.

PMID:
29684376
2.

Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations.

Cabana J, Holleran B, Leduc R, Escher E, Guillemette G, Lavigne P.

J Biol Chem. 2015 Jun 19;290(25):15835-54. doi: 10.1074/jbc.M114.627356. Epub 2015 May 1.

3.

Characterization of Angiotensin II Molecular Determinants Involved in AT1 Receptor Functional Selectivity.

Domazet I, Holleran BJ, Richard A, Vandenberghe C, Lavigne P, Escher E, Leduc R, Guillemette G.

Mol Pharmacol. 2015 Jun;87(6):982-95. doi: 10.1124/mol.114.097337. Epub 2015 Mar 25.

4.

STIM1 positively regulates the Ca2+ release activity of the inositol 1,4,5-trisphosphate receptor in bovine aortic endothelial cells.

Béliveau É, Lessard V, Guillemette G.

PLoS One. 2014 Dec 15;9(12):e114718. doi: 10.1371/journal.pone.0114718. eCollection 2014.

5.

Mechanism of dopamine D2 receptor-induced Ca(2+) release in PC-12 cells.

Frégeau MO, Carrier M, Guillemette G.

Cell Signal. 2013 Dec;25(12):2871-7. doi: 10.1016/j.cellsig.2013.08.021. Epub 2013 Sep 19.

PMID:
24055909
6.

STIM1 participates in the contractile rhythmicity of HL-1 cells by moderating T-type Ca(2+) channel activity.

Nguyen N, Biet M, Simard E, Béliveau E, Francoeur N, Guillemette G, Dumaine R, Grandbois M, Boulay G.

Biochim Biophys Acta. 2013 Jun;1833(6):1294-303. doi: 10.1016/j.bbamcr.2013.02.027. Epub 2013 Feb 28.

7.

Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode.

Fillion D, Cabana J, Guillemette G, Leduc R, Lavigne P, Escher E.

J Biol Chem. 2013 Mar 22;288(12):8187-97. doi: 10.1074/jbc.M112.442053. Epub 2013 Feb 5.

8.

Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor.

Cabana J, Holleran B, Beaulieu MÈ, Leduc R, Escher E, Guillemette G, Lavigne P.

J Biol Chem. 2013 Jan 25;288(4):2593-604. doi: 10.1074/jbc.M112.395939. Epub 2012 Dec 7.

9.

Type 1 inositol-1,4,5-trisphosphate receptor is a late substrate of caspases during apoptosis.

Elkoreh G, Blais V, Béliveau E, Guillemette G, Denault JB.

J Cell Biochem. 2012 Aug;113(8):2775-84. doi: 10.1002/jcb.24155.

PMID:
22473799
10.

The activation state of the inositol 1,4,5-trisphosphate receptor regulates the velocity of intracellular Ca2+ waves in bovine aortic endothelial cells.

Béliveau È, Lapointe F, Guillemette G.

J Cell Biochem. 2011 Dec;112(12):3722-31. doi: 10.1002/jcb.23301.

PMID:
21815194
11.

Positive regulation of inositol 1,4,5-trisphosphate-induced Ca2+ release by mammalian target of rapamycin (mTOR) in RINm5F cells.

Frégeau MO, Régimbald-Dumas Y, Guillemette G.

J Cell Biochem. 2011 Feb;112(2):723-33. doi: 10.1002/jcb.23006.

PMID:
21268094
12.

The transcription factors NFAT and CREB have different susceptibilities to the reduced Ca2+ responses caused by the knock down of inositol trisphosphate receptor in HEK 293A cells.

Arguin G, Caron AZ, Elkoreh G, Denault JB, Guillemette G.

Cell Physiol Biochem. 2010;26(4-5):629-40. doi: 10.1159/000322330. Epub 2010 Oct 29.

13.

Mammalian target of rapamycin (mTOR) phosphorylates inositol 1,4,5-trisphosphate receptor type 2 and increases its Ca(2+) release activity.

Régimbald-Dumas Y, Frégeau MO, Guillemette G.

Cell Signal. 2011 Jan;23(1):71-9. doi: 10.1016/j.cellsig.2010.08.005. Epub 2010 Aug 18.

PMID:
20727967
14.

Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism.

Arsenault J, Cabana J, Fillion D, Leduc R, Guillemette G, Lavigne P, Escher E.

Biochem Pharmacol. 2010 Oct 1;80(7):990-9. doi: 10.1016/j.bcp.2010.06.004. Epub 2010 Jun 19.

PMID:
20599798
15.

A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.

Arsenault J, Lehoux J, Lanthier L, Cabana J, Guillemette G, Lavigne P, Leduc R, Escher E.

Pharmacogenet Genomics. 2010 Jun;20(6):377-88. doi: 10.1097/FPC.0b013e32833a6d4a.

PMID:
20436376
16.

The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.

Fillion D, Lemieux G, Basambombo LL, Lavigne P, Guillemette G, Leduc R, Escher E.

J Med Chem. 2010 Mar 11;53(5):2063-75. doi: 10.1021/jm9015747.

PMID:
20146480
17.

Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis.

Yan L, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R.

J Biol Chem. 2010 Jan 22;285(4):2284-93. doi: 10.1074/jbc.M109.077180. Epub 2009 Nov 23.

18.

The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.

Domazet I, Martin SS, Holleran BJ, Morin ME, Lacasse P, Lavigne P, Escher E, Leduc R, Guillemette G.

J Biol Chem. 2009 Nov 13;284(46):31953-61. doi: 10.1074/jbc.M109.051839. Epub 2009 Sep 22.

19.

Activation induces structural changes in the liganded angiotensin II type 1 receptor.

Clément M, Cabana J, Holleran BJ, Leduc R, Guillemette G, Lavigne P, Escher E.

J Biol Chem. 2009 Sep 25;284(39):26603-12. doi: 10.1074/jbc.M109.012922. Epub 2009 Jul 27.

20.

Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.

Holleran BJ, Domazet I, Beaulieu ME, Yan LP, Guillemette G, Lavigne P, Escher E, Leduc R.

Biochem Pharmacol. 2009 Apr 15;77(8):1374-82. doi: 10.1016/j.bcp.2009.01.013. Epub 2009 Jan 29.

PMID:
19426676
21.

Structural changes in the binding pocket of the liganded angiotensin II receptor AT1 during activation.

Clément M, Guillemette G, Leduc R, Escher E.

Adv Exp Med Biol. 2009;611:341-2. No abstract available.

PMID:
19400219
22.

Temperature-induced ligand contact point variations of the hAT1 receptor and of the constitutively active mutant N111G-hAT1.

Arsenault J, Renaud MP, Clément M, Fillion D, Guillemette G, Leduc R, Lavigne P, Escher E.

Adv Exp Med Biol. 2009;611:339-40. No abstract available.

PMID:
19400218
23.

Photoprobe peptides to map the interactions of angiotensin II with its receptor AT1.

Fillion D, Guillemette G, Leduc R, Escher E.

Adv Exp Med Biol. 2009;611:329-30. No abstract available.

PMID:
19400214
24.

The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation.

Domazet I, Holleran BJ, Martin SS, Lavigne P, Leduc R, Escher E, Guillemette G.

J Biol Chem. 2009 May 1;284(18):11922-9. doi: 10.1074/jbc.M808113200. Epub 2009 Mar 9.

25.

Insulin promotes the association of heat shock protein 90 with the inositol 1,4,5-trisphosphate receptor to dampen its Ca2+ release activity.

Nguyen N, Francoeur N, Chartrand V, Klarskov K, Guillemette G, Boulay G.

Endocrinology. 2009 May;150(5):2190-6. doi: 10.1210/en.2008-1167. Epub 2009 Jan 15.

PMID:
19147678
26.
27.

Real-time monitoring of angiotensin II-induced contractile response and cytoskeleton remodeling in individual cells by atomic force microscopy.

Cuerrier CM, Benoit M, Guillemette G, Gobeil F Jr, Grandbois M.

Pflugers Arch. 2009 Apr;457(6):1361-72. doi: 10.1007/s00424-008-0596-0. Epub 2008 Oct 25.

PMID:
18953565
28.

Memantine potentiates agonist-induced Ca2+ responses in HEK 293 cells.

Blanchard AP, Guillemette G, Boulay G.

Cell Physiol Biochem. 2008;22(1-4):205-14. doi: 10.1159/000149798. Epub 2008 Jul 25.

29.

Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor.

Proulx CD, Holleran BJ, Boucard AA, Escher E, Guillemette G, Leduc R.

Mol Pharmacol. 2008 Sep;74(3):552-61. doi: 10.1124/mol.108.045054. Epub 2008 May 28.

30.

Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells.

Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VA, Jones JE, Wang Z, Periasamy A, Lau YS, Soares-da-Silva P, Creswell K, Guillemette G, Sibley DR, Eisner G, Gildea JJ, Felder RA, Jose PA.

J Clin Invest. 2008 Jun;118(6):2180-9. doi: 10.1172/JCI33637. Erratum in: J Clin Invest. 2008 Aug;118(8):2986. Gildea, John J [added].

31.

Biological properties and functional determinants of the urotensin II receptor.

Proulx CD, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R.

Peptides. 2008 May;29(5):691-9. Epub 2007 Nov 17. Review.

PMID:
18155322
32.

Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II.

Leclerc PC, Proulx CD, Arguin G, Bélanger S, Gobeil F Jr, Escher E, Leduc R, Guillemette G.

Am J Hypertens. 2008 Jan;21(1):67-71.

PMID:
18091746
33.

Temperature-dependent variations of ligand-receptor contact points in hAT(1).

Arsenault J, Renaud MP, Clément M, Fillion D, Guillemette G, Leduc R, Lavigne P, Escher E.

J Pept Sci. 2007 Sep;13(9):575-80.

PMID:
17600857
34.

Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method.

Martin SS, Holleran BJ, Escher E, Guillemette G, Leduc R.

Mol Pharmacol. 2007 Jul;72(1):182-90. Epub 2007 Apr 19.

36.

Protein kinase C phosphorylates the inositol 1,4,5-trisphosphate receptor type 2 and decreases the mobilization of Ca2+in pancreatoma AR4-2J cells.

Arguin G, Regimbald-Dumas Y, Fregeau MO, Caron AZ, Guillemette G.

J Endocrinol. 2007 Mar;192(3):659-68.

37.

Protein kinase C decreases the apparent affinity of the inositol 1,4,5-trisphosphate receptor type 3 in RINm5F cells.

Caron AZ, Chaloux B, Arguin G, Guillemette G.

Cell Calcium. 2007 Sep;42(3):323-31. Epub 2007 Feb 23.

PMID:
17320950
38.

cAMP-dependent protein kinase enhances inositol 1,4,5-trisphosphate-induced Ca2+ release in AR4-2J cells.

Regimbald-Dumas Y, Arguin G, Fregeau MO, Guillemette G.

J Cell Biochem. 2007 Jun 1;101(3):609-18.

PMID:
17203464
39.

The active and the inactive form of the hAT1 receptor have an identical ligand-binding environment: an MPA study on a constitutively active angiotensin II receptor mutant.

Clément M, Chamberland C, Pérodin J, Leduc R, Guillemette G, Escher E.

J Recept Signal Transduct Res. 2006;26(5-6):417-33.

PMID:
17118790
40.

S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II.

Leclerc PC, Lanctot PM, Auger-Messier M, Escher E, Leduc R, Guillemette G.

Br J Pharmacol. 2006 Jun;148(3):306-13.

41.

Role of N-glycan-dependent quality control in the cell-surface expression of the AT1 receptor.

Lanctôt PM, Leclerc PC, Escher E, Guillemette G, Leduc R.

Biochem Biophys Res Commun. 2006 Feb 10;340(2):395-402. Epub 2005 Dec 13.

PMID:
16364240
42.

The constitutively active N111G-AT1 receptor for angiotensin II modifies the morphology and cytoskeletal organization of HEK-293 cells.

Auger-Messier M, Turgeon ES, Leduc R, Escher E, Guillemette G.

Exp Cell Res. 2005 Aug 1;308(1):188-95.

PMID:
15896777
43.

Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay.

Clément M, Martin SS, Beaulieu ME, Chamberland C, Lavigne P, Leduc R, Guillemette G, Escher E.

J Biol Chem. 2005 Jul 22;280(29):27121-9. Epub 2005 May 12.

44.

Importance of N-glycosylation positioning for cell-surface expression, targeting, affinity and quality control of the human AT1 receptor.

Lanctot PM, Leclerc PC, Clément M, Auger-Messier M, Escher E, Leduc R, Guillemette G.

Biochem J. 2005 Aug 15;390(Pt 1):367-76.

45.

A fluorogenic substrate for the continuous assaying of aryl sulfatases.

Ahmed V, Ispahany M, Ruttgaizer S, Guillemette G, Taylor SD.

Anal Biochem. 2005 May 1;340(1):80-8.

PMID:
15802133
46.

Synthesis of (+/-)-2-O-[4'-(N-9''-purinyl)butyl] myo-inositol 1,4,5-tris(phosphate), a potent full agonist at the D-myo-inositol 1,4,5-tris(phosphate) receptor.

Moris MA, Caron AZ, Guillemette G, Rognan D, Schmitt M, Schlewer G.

J Med Chem. 2005 Feb 24;48(4):1251-5.

PMID:
15715492
47.

Expression of a truncated form of inositol 1,4,5-trisphosphate receptor type III in the cytosol of DT40 triple inositol 1,4,5-trisphosphate receptor-knockout cells.

Guillemette J, Caron AZ, Regimbald-Dumas Y, Arguin G, Mignery GA, Boulay G, Guillemette G.

Cell Calcium. 2005 Feb;37(2):97-104.

PMID:
15589990
48.

Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.

Proulx CD, Simaan M, Escher E, Laporte SA, Guillemette G, Leduc R.

Biochem J. 2005 Jan 1;385(Pt 1):115-23.

49.

Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis.

Martin SS, Boucard AA, Clément M, Escher E, Leduc R, Guillemette G.

J Biol Chem. 2004 Dec 3;279(49):51415-23. Epub 2004 Sep 27.

50.

Down-regulation of inositol 1,4,5-trisphosphate receptor in cells stably expressing the constitutively active angiotensin II N111G-AT(1) receptor.

Auger-Messier M, Arguin G, Chaloux B, Leduc R, Escher E, Guillemette G.

Mol Endocrinol. 2004 Dec;18(12):2967-80. Epub 2004 Aug 26.

PMID:
15331757

Supplemental Content

Loading ...
Support Center